Table 4. Functional progression (Health Assessment Questionnaire Disability Index (HAQ-DI)) across the European League Against Rheumatism (EULAR) states based on the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte sedimentation rate(ESR): mean change from baseline.
| Trial | EULAR response | Abatacept group | Placebo group | Combined group | |||
| CRP | ESR | CRP | ESR | CRP | ESR | ||
| (n = 171) | (n = 75) | (n = 246) | |||||
| ATTAIN (6 months) | Good | −1.00 (0.10) | −0.82 (0.13) | −0.56 (0.28) | −0.63 (0.38) | −0.95 (0.09) | −0.80 (0.12) |
| Moderate | −0.49 (0.06) | −0.56 (0.06) | −0.21 (0.06) | −0.28 (0.06) | −0.43 (0.05) | −0.50 (0.05) | |
| None | −0.18 (0.06) | −0.21 (0.05) | −0.10 (0.06) | −0.07 (0.06) | −0.14 (0.04) | −0.14 (0.04) | |
| (n = 351) | (n = 155) | (n = 506) | |||||
| AIM (6 months) | Good | −0.89 (0.06) | −0.97 (0.07) | −1.03 (0.16) | −1.20 (0.24) | −0.91 (0.05) | −0.99 (0.06) |
| Moderate | −0.55 (0.04) | −0.57 (0.04) | −0.66 (0.06) | −0.71 (0.07) | −0.59 (0.03) | −0.61 (0.03) | |
| None | −0.11 (0.05) | −0.16 (0.06) | −0.18 (0.07) | −0.20 (0.07) | −0.15 (0.05) | −0.18 (0.05) | |
Data are mean (SD).
AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders.